Discovery of Reversible Covalent Bruton’s Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib)

Timothy D. Owens, Ken A. Brameld, Erik J. Verner, Tony Ton, Xiaoyan Li, Jiang Zhu, Mohammad R. Masjedizadeh, J. Michael Bradshaw, Ronald J. Hill, Danny Tam, Angelina Bisconte, Eun Ok Kim, Michelle Francesco, Yan Xing, Jin Shu, Dane Karr, Jacob LaStant, David Finkle, Natalie Loewenstein, Helena Haberstock-Debic, Michael J. Taylor, Philip Nunn, Claire L. Langrish, David M. Goldstein

Open source

DOI: 10.1021/acs.jmedchem.1c01170
Published: 2022-03-18
Container: Journal of Medicinal Chemistry
Publisher: American Chemical Society (ACS)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1021/acs.jmedchem.1c01170,
  title = {Discovery of Reversible Covalent Bruton’s Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib)},
  author = {Timothy D. Owens and Ken A. Brameld and Erik J. Verner and Tony Ton and Xiaoyan Li and Jiang Zhu and Mohammad R. Masjedizadeh and J. Michael Bradshaw and Ronald J. Hill and Danny Tam and Angelina Bisconte and Eun Ok Kim and Michelle Francesco and Yan Xing and Jin Shu and Dane Karr and Jacob LaStant and David Finkle and Natalie Loewenstein and Helena Haberstock-Debic and Michael J. Taylor and Philip Nunn and Claire L. Langrish and David M. Goldstein},
  year = {2022},
  journal = {Journal of Medicinal Chemistry},
  doi = {10.1021/acs.jmedchem.1c01170},
  url = {https://doi.org/10.1021/acs.jmedchem.1c01170}
}

RIS

TY  - JOUR
TI  - Discovery of Reversible Covalent Bruton’s Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib)
AU  - Timothy D. Owens
AU  - Ken A. Brameld
AU  - Erik J. Verner
AU  - Tony Ton
AU  - Xiaoyan Li
AU  - Jiang Zhu
AU  - Mohammad R. Masjedizadeh
AU  - J. Michael Bradshaw
AU  - Ronald J. Hill
AU  - Danny Tam
AU  - Angelina Bisconte
AU  - Eun Ok Kim
AU  - Michelle Francesco
AU  - Yan Xing
AU  - Jin Shu
AU  - Dane Karr
AU  - Jacob LaStant
AU  - David Finkle
AU  - Natalie Loewenstein
AU  - Helena Haberstock-Debic
AU  - Michael J. Taylor
AU  - Philip Nunn
AU  - Claire L. Langrish
AU  - David M. Goldstein
PY  - 2022
JO  - Journal of Medicinal Chemistry
DO  - 10.1021/acs.jmedchem.1c01170
UR  - https://doi.org/10.1021/acs.jmedchem.1c01170
ER  -

APA

Owens, T. D., Brameld, K. A., Verner, E. J., Ton, T., Li, X., Zhu, J., Masjedizadeh, M. R., Bradshaw, J. M., Hill, R. J., Tam, D., Bisconte, A., Kim, E. O., Francesco, M., Xing, Y., Shu, J., Karr, D., LaStant, J., Finkle, D., Loewenstein, N., Haberstock-Debic, H., Taylor, M. J., Nunn, P., Langrish, C. L., & Goldstein, D. M. (2022). Discovery of Reversible Covalent Bruton’s Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib). Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.1c01170

Source records

crossref · retrieved 2026-09-27T08:54:32.843Z